RxDoctor Payments DataLook up a doctor →

Erin Hernandez, NP

Acute Care · San Antonio, TXNPI 1760836183

Payments from drug & device makers

$9,979in general payments, 2019–2025

Across 359 payments — averaging $27.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Astellas Pharma US Inc$785
  • Johnson & Johnson$652
  • E.r. Squibb & Sons, L.L.C.$516
  • AstraZeneca$475
  • Incyte Corporation$430
  • plus $6K from 53 others

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific11$1,436
Astellas Pharma US Inc22$785
Johnson & Johnson30$652
E.r. Squibb & Sons, L.L.C.11$516
AstraZeneca(2 entities)21$475
Incyte Corporation17$430
Bristol Myers Squibb20$424
Pfizer20$423
Seagen Inc.8$318
Bayer8$263
Takeda Pharmaceuticals U.S.A., Inc.10$249
Karyopharm Therapeutics Inc.14$247
Novartis9$239
Amgen9$178
Sanofi8$174
Sobi, Inc7$171
Genmab U.S., Inc.6$159
Regeneron Healthcare Solutions, Inc.6$157
Pharmaessentia USA Corporation5$150
Lilly USA, LLC7$144
Gilead7$140
Sumitomo Pharma America, Inc.6$135
GSK6$127
Daiichi Sankyo Inc.6$118
Ipsen Biopharmaceuticals, Inc7$117
Morphosys, US Inc.5$113
Taiho Oncology, Inc.6$113
Genentech USA, Inc.5$110
Merck4$94
Rigel Pharmaceuticals, Inc.5$94
Blueprint Medicines Corporation4$79
EMD Serono, Inc.4$79
Sanofi-aventis U.S. LLC1$75
Apellis Pharmaceuticals, Inc.4$73
Mirati Therapeutics, Inc.3$66
Spectrum Pharmaceuticals Inc.3$65
Dendreon Pharmaceuticals LLC2$64
Olympus America Inc.2$60
Stemline Therapeutics Inc.2$56
Tolmar, Inc.3$54
Tersera Therapeutics LLC2$53
AbbVie2$49
CTI Biopharma Corp.2$44
Fennec Pharmaceuticals, Inc.2$44
Medtronic1$40
Puma Biotechnology, Inc.2$40
AVEO Pharmaceuticals, Inc.2$36
Caris MPI, Inc.1$30
Boehringer Ingelheim1$30
Jazz Pharmaceuticals Inc.1$25
Deciphera Pharmaceuticals Inc.1$22
Kyowa Kirin, Inc.1$21
Octapharma USA, Inc.1$20
ADC Therapeutics America, Inc.1$19
Array Biopharma Inc1$18
Pharmacosmos Therapeutics Inc.1$18
Eisai Inc.1$17
Agios Pharmaceuticals, Inc.1$15
Axonics, Inc.1$14

How this compares

$9,979 in reported general payments places this provider in the 95th percentile of 2,323 acute care providers in Texas.

See all acute care providers in Texas →

Medicare billing

Part B allowed, 2024
$3,655
Medicare patients
18
Services billed
116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other acute care in San Antonio

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →